3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Surveys and Questionnaires
9
Standard of Care
5
Endoscopic Mucosal Resection
5
Educational Status
5
Blood Specimen Collection
5
Diet Therapy
3
Referral and Consultation
2
Quality of Life
2
Practice Guidelines as Topic
2
Palliative Care
2
Magnetic Resonance Spectroscopy
2
Interviews as Topic
2
Control Groups
2
Aprepitant
2
Acceptance and Commitment Therapy
2
vandetanib
1
fosaprepitant
1
dolasetron
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
auricularum
1
Weights and Measures
1
Tomography, X-Ray Computed
1
Therapeutics
1
Surgical Instruments
1
Sunitinib
1
Sorafenib
1
Sampling Studies
1
Restraint, Physical
1
Remote Patient Monitoring
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Gastrointestinal Neoplasms
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled